Romosozumab in severe postmenopausal osteoporosis—real-world data from 192 women
- 1Department for Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Lottestrasse 59, Hamburg, 22529 Germany
- 2MVZ Osteologie, University Medical Center Hamburg-Eppendorf, Lottestrasse 59, Hamburg, 22529 Germany
Abstract
Romosozumab, used to treat severe osteoporosis, still lacks real-world treatment data. We observed significant gains in spinal and hip bone mineral density, as well as improvements in trabecular microarchitecture. These real-world observations corroborate controlled trials and provide new insights into sequential therapy effects and the management of severe osteoporosis.
Purpose: Osteoporosis is a common disease that leads to fractures causing immobility and pain. Pharmacological therapy plays a pivotal role in osteoporosis management with a growing number of approved drugs. Romosozumab, an anti-sclerostin antibody, is approved in several countries for the treatment of severe osteoporosis in postmenopausal women. Clinical trials have demonstrated significant gain of areal bone mineral density (aBMD) in these patients over 12 months of treatment; however, real-world data is still limited.
Methods: From 2020 to 2024, 192 postmenopausal women with severe osteoporosis treated with romosozumab were identified at our institution. Clinical data from a 24-month observation period were analyzed, comprising aBMD by dual-energy X-ray absorptiometry (DXA), bone microstructure by high-resolution peripheral quantitative computed tomography (HR-pQCT), and biochemical bone turnover markers.
Results: Patients treated with romosozumab showed significant gains in spinal (L1–L4) and hip aBMD (lumbar spine: 14.47 ± 8.74%, p < 0.001; total hip: 4.15 ± 5.92%, p < 0.001), accompanied by an increase in bone formation parameters after 6 months and an increase in trabecular microarchitectural parameters assessed by HR-pQCT in 12-month follow-up. These changes were significantly lower in patients with previous bone specific treatment. Treatment-naïve (TN) patients benefited significantly more than those previously treated with antiresorptive (AR) medication (lumbar spine aBMD change: TN: 17.74 ± 8.30%, AR: 10.44 ± 7.67%, p < 0.001). This was supported by the dependency of aBMD gain on baseline bone formation markers.
Conclusion: Our real-world data corroborate the results from controlled studies and provide new insights into microstructural changes as well as biochemical treatment monitoring. To fully evaluate sequential therapy, larger studies and longer observation times are needed in the future.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s00198-026-08127-x.
Related
- 24-month real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Australia, Taiwan, South Korea, Hong Kong, and Singapore
- Association of elevated circulating iron with bone mineral density and bone turnover markers in postmenopausal Saudi women with and without osteoporosis
- Eldecalcitol and calcium supplementation in Chinese women with postmenopausal osteoporosis: a prospective observational cohort study
- Prevalence and risk factors of postmenopausal osteoporosis: a systematic review and meta-analysis based on multivariate logistic regression
- Physical and lifestyle predictors of vascular function in postmenopausal East Asian women: the women’s vascular health project
BibTeX
@article{dehne2026romosozumab,
title = {{Romosozumab in severe postmenopausal osteoporosis—real-world data from 192 women}},
author = {Nicolas Dehne and Felix N. von Brackel and Claudia Günzl and Florian Barvencik and Ralf Oheim},
journal = {Osteoporosis International},
year = {2026},
month = jul,
doi = {10.1007/s00198-026-08127-x},
url = {https://doi.org/10.1007/s00198-026-08127-x},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Romosozumab in severe postmenopausal osteoporosis—real-world data from 192 women
AU - Nicolas Dehne
AU - Felix N. von Brackel
AU - Claudia Günzl
AU - Florian Barvencik
AU - Ralf Oheim
PY - 2026
DA - 2026/07/08
JO - Osteoporosis International
DO - 10.1007/s00198-026-08127-x
UR - https://doi.org/10.1007/s00198-026-08127-x
AB - Romosozumab, used to treat severe osteoporosis, still lacks real-world treatment data. We observed significant gains in spinal and hip bone mineral density, as well as improvements in trabecular microarchitecture. These real-world observations corroborate controlled trials and provide new insights into sequential therapy effects and the management of severe osteoporosis. Purpose: Osteoporosis is a common disease that leads to fractures causing immobility and pain. Pharmacological therapy plays a pivotal role in osteoporosis management with a growing number of approved drugs. Romosozumab, an anti-sclerostin antibody, is approved in several countries for the treatment of severe osteoporosis in postmenopausal women. Clinical trials have demonstrated significant gain of areal bone mineral density (aBMD) in these patients over 12 months of treatment; however, real-world data is still limited. Methods: From 2020 to 2024, 192 postmenopausal women with severe osteoporosis treated with romosozumab were identified at our institution. Clinical data from a 24-month observation period were analyzed, comprising aBMD by dual-energy X-ray absorptiometry (DXA), bone microstructure by high-resolution peripheral quantitative computed tomography (HR-pQCT), and biochemical bone turnover markers. Results: Patients treated with romosozumab showed significant gains in spinal (L1–L4) and hip aBMD (lumbar spine: 14.47 ± 8.74%, p < 0.001; total hip: 4.15 ± 5.92%, p < 0.001), accompanied by an increase in bone formation parameters after 6 months and an increase in trabecular microarchitectural parameters assessed by HR-pQCT in 12-month follow-up. These changes were significantly lower in patients with previous bone specific treatment. Treatment-naïve (TN) patients benefited significantly more than those previously treated with antiresorptive (AR) medication (lumbar spine aBMD change: TN: 17.74 ± 8.30%, AR: 10.44 ± 7.67%, p < 0.001). This was supported by the dependency of aBMD gain on baseline bone formation markers. Conclusion: Our real-world data corroborate the results from controlled studies and provide new insights into microstructural changes as well as biochemical treatment monitoring. To fully evaluate sequential therapy, larger studies and longer observation times are needed in the future. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s00198-026-08127-x.
SN - 0937-941X
SN - 1433-2965
ER -